NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

Author's Avatar
Jan 11, 2022

FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") has received the CE mark for its RaDaRâ„¢ assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC). In addition, Inivata has submitted to the MolDX program in the US for the reimbursement of RaDaR for clinical testing.